The GoodRX (GDRX) on Monday joins the GLP-1 action with a report that it will start selling both Novo Nordisk (NGO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss at a net price of $ 499 per month.
Partnership occurs when remote health and digital health platforms are increasingly regarded as ways to provide more access to demand products.
Wendy Barnes, CEO of GoodRX, told Yahoo Finance that although the company is not first from the gate with a strategy, she thinks it comes at the right time.
“We have no doubt that we could try to do something more quickly from the complex alternative road, but it was very clear to us that the FDA was confirmed, legally confirmed. It was simply not the path we supported,” Barnes said.
This message has increased the Goodrx stock, ie more than 30% of trade on Monday.
Remote health platforms such as HES and HER (HERS) have recently been under pressure after Novo Nordisk has completed contact with the company, when HIMS and hero refused to stop selling compounds or copy the GLP-1S versions.
The complex version of popular drugs on the market was several years and initially allowed FDA when Novo Nordisk and Eli Lilly (LLY) competitor could not satisfy their GLP-1 market demand. After the disadvantage, Copycats is now illegal, but pharmacies and their sellers claim that they are lawfully sold through the law of the law called Personalized Medicine. If the patient is unable to tolerate the side effects of the drug, a complex version is often used.
“There are very serious reasons to use compound drugs that are clinically appropriate and acceptable. It is not where everything is sitting in this drug class,” Barnes said.
The sale of injections via GoodRX is also different from Eli Lilly’s strategy, which has been selling their products bottles on Telehealth platforms to get more patients faster. Bottles are easier to produce than injection pens, which were the main reason for the last two years.
Goodrx said she had noticed the increasing demand for GLP-1 products-in the year, there were 17 million inquiries on her website. It increased 22% than a year ago. Ozempic sales via GoodRX marks the first time when a diabetes drug is sold at cash, GoodRX said.
Goodrx also sells Eli Lilly drugs for Mounjar (diabetes) and Zepbound through regular medicinal channels at normal prices.